XM does not provide services to residents of the United States of America.
F
F

FreseniusMedical

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

AbbVie's tight grip on Humira market raises concerns about biosimilars

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
A
C
P
T
F

Fresenius lifts 2024 targets for private healthcare unit Helios

Fresenius lifts 2024 targets for private healthcare unit Helios June 5 (Reuters) - German healthcare group Fresenius FREG.DE raised the yearly guidance for its private healthcare provider Helios on Wednesday, following a strong start to 2024 and the conclusion of group-wide restructuring. The Hessian-based group expects Helios to grow its revenue by a mid-single-digit percentage and report an earnings before interests and taxes (EBIT) margin of 10% to 11% this year.
F
F

Top of the Street: Fresenius, Freenet, European tyremakers

BUZZ-Top of the Street: Fresenius, Freenet, European tyremakers A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** UBS upgrades mobile retailer and service provider Freenet FNTGn.DE to "buy" from "hold", saying it benefits from competitive tensions in the German mobile market that have pushed operators to give it longer term deals ** HSBC raises German healthcare group Fresenius FREG.DE to "buy" from "hold" and increases its TP by 23% to 38 euros INITIATION
C
F
F
H
F

OEBAG Sells 13% Stake In Vamed To Fresenius

BRIEF-OEBAG Sells 13% Stake In Vamed To Fresenius June 4 (Reuters) - OEBAG says: SELLS 13% STAKE IN VAMED TO FRESENIUS PARTIES HAVE AGREED NOT TO DISCLOSE THE PURCHASE PRICE Further company coverage: FMEG.DE (Gdansk Newsroom)
F

Allianz, Carnival, Future

EUROPE RESEARCH ROUNDUP-Allianz, Carnival, Future June 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz, Carnival and Future, on Tuesday. HIGHLIGHTS * Allianz SE ALVG.DE : Citigroup cuts to neutral from buy * Carnival CCL.L : Peel Hunt raises to buy from add * Future Plc FUTR.L : Berenberg raises to buy from hold * Liontrust Asset Management Plc LIO.L : Deutsche Bank cuts to sell from hold * Nibe NIBEB.ST : Barclays cuts t
A
A
C
D
F
F
H
I
I
K
L
L
M
N
P
R
A
A
A
B
F
P
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.